Myriad Genetics to Present at the Goldman Sachs Global Healthcare Conference
June 03 2014 - 7:05AM
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D.
Meldrum, president and CEO of Myriad, is scheduled to present at
the 35th annual Goldman Sachs Global Healthcare
Conference
, at 10:40 a.m. Pacific on June 10,
2014, at the Terranea Resort in Rancho Palos Verdes, California.
The presentation will be available to interested parties through
a live audio webcast accessible through a link on the investor
relations section of Myriad's website at www.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company
dedicated to making a difference in patients' lives through the
discovery and commercialization of transformative tests to assess a
person's risk of developing disease, guide treatment decisions and
assess risk of disease progression and recurrence. Myriad's
molecular diagnostic tests are based on an understanding of the
role genes play in human disease and were developed with a
commitment to improving an individual's decision making process for
monitoring and treating disease. Myriad is focused on strategic
directives to introduce new products, including companion
diagnostics, as well as expanding internationally. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
CONTACT: Media Contact: Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact: Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024